C. Horak

发表

Complex transcriptional circuitry at the G1/S transition in Saccharomyces cerevisiae.

M. Gerstein, J. Qian, N. Luscombe, 2002, Genes & development.

Genomic binding sites of the yeast cell-cycle transcription factors SBF and MBF

D. Botstein, P. Brown, V. Iyer, 2001, Nature.

Nivolumab plus ipilimumab in advanced melanoma.

C. Horak, J. Wolchok, M. Sznol, 2013, The New England journal of medicine.

Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancer.

C. Horak, T. Lynch, S. Khambata-Ford, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.

G. Linette, C. Horak, P. Ascierto, 2015, The Lancet. Oncology.

GATA-1 binding sites mapped in the β-globin locus by using mammalian chIp-chip analysis

M. Gerstein, Michael P. Snyder, M. Mahajan, 2002, Proceedings of the National Academy of Sciences of the United States of America.

Establishing a complementary diagnostic for anti-PD-1 immune checkpoint inhibitor therapy

C. Horak, H. Inzunza, C. Harbison, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Association of Tumor Microenvironment T-cell Repertoire and Mutational Load with Clinical Outcome after Sequential Checkpoint Blockade in Melanoma

David M. Woods, M. Vignali, R. Wilson, 2019, Cancer Immunology Research.

ChIP-chip: a genomic approach for identifying transcription factor binding sites.

Michael Snyder, M. Snyder, C. Horak, 2002, Methods in enzymology.

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.

Dirk Schadendorf, Reinhard Dummer, Paolo A Ascierto, 2015, The New England journal of medicine.

The role of metastasis suppressor genes in metastatic dormancy.

C. Horak, P. Steeg, S. Shreeve, 2008, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

The role of metastasis suppressor genes in metastatic dormancy

C. Horak, P. Steeg, S. Shreeve, 2008 .

Long-term survival of ipilimumab-naive patients (pts) with advanced melanoma (MEL) treated with nivolumab (anti-PD-1, BMS-936558, ONO-4538) in a phase I trial.

J. Taube, C. Horak, M. Atkins, 2014 .

Abstract CT075: Overall survival (OS) results from a phase III trial of nivolumab (NIVO) combined with ipilimumab (IPI) in treatment-naïve patients with advanced melanoma (CheckMate 067)

D. Schadendorf, C. Horak, R. Dummer, 2017 .

NeoadjuvantDoxorubicin / CyclophosphamideFollowedby IxabepiloneorPaclitaxel inEarly StageBreastCancerandEvaluationof III-TubulinExpressionasaPredictiveMarker

Cynthia, C. Horak, F. Symmans, 2013 .

Association of tumor PD-L1 expression and immune biomarkers with clinical activity in patients (pts) with advanced solid tumors treated with nivolumab (anti-PD-1; BMS-936558; ONO-4538).

Clive R. Taylor, J. Taube, C. Horak, 2013 .

Nm23-H1 suppresses metastasis by inhibiting expression of the lysophosphatidic acid receptor EDG2.

S. Steinberg, C. Horak, M. Merino, 2007, Cancer research.

Clinical-Translational Approaches to the Nm23-H1 Metastasis Suppressor

C. Horak, P. Steeg, K. Miller, 2008, Clinical Cancer Research.

K-Ras mutation (mut), EGFR-related, and exploratory markers as response predictors of cetuximab in first-line advanced NSCLC: Retrospective analyses of the BMS099 trial.

C. Horak, T. Lynch, S. Khambata-Ford, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Metabolomic adaptations and correlates of survival to immune checkpoint blockade

W. Sellers, S. Schreiber, L. Garraway, 2019, Nature Communications.

Two-year overall survival rates from a randomised phase 2 trial evaluating the combination of nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma

G. Linette, C. Horak, J. Wolchok, 2017 .

CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study.

Christopher R. Cabanski, Lacey J. Kitch, Vanessa M. Hubbard-Lucey, 2021, The Lancet. Oncology.

Metabolomic correlates of response in nivolumab-treated renal cell carcinoma and melanoma patients.

L. Garraway, C. Horak, T. Choueiri, 2017 .

Nivolumab and ipilimumab versus ipilimumab in untreated melanoma.

G. Linette, C. Horak, J. Wolchok, 2015, The New England journal of medicine.

High β-III tubulin expression in triple-negative (TN) breast cancer (BC) subtype and correlation to ixabepilone response: A retrospective analysis.

C. Horak, J. Baselga, F. Lee, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Potential Predictive Markers of Benefit from Cetuximab in Metastatic Breast Cancer: An Analysis of Two Randomized Phase 2 Trials.

Mark T. W. Ebbert, C. Perou, K. Hoadley, 2009 .

Translational approaches using metastasis suppressor genes

C. Horak, P. Steeg, D. Palmieri, 2006, Journal of bioenergetics and biomembranes.

Peripheral and tumor immune correlates in patients with advanced melanoma treated with nivolumab (anti-PD-1, BMS-936558, ONO-4538) monotherapy or in combination with ipilimumab

J. Taube, C. Horak, J. Wolchok, 2014, Journal of Translational Medicine.

Clinical-Translational Approaches to the Nm23-H1

C. Horak, P. Steeg, K. Miller, 2008 .

Baseline tumor T cell receptor (TcR) sequencing analysis and neo antigen load is associated with benefit in melanoma patients receiving sequential nivolumab and ipilimumab

C. Horak, F. Hodi, D. Woods, 2016 .

Abstract CT001: Durable, long-term survival in previously treated patients with advanced melanoma (MEL) who received nivolumab (NIVO) monotherapy in a phase I trial

J. Taube, C. Horak, M. Atkins, 2016 .

Nivolumab in previously untreated melanoma without BRAF mutation.

D. Schadendorf, K. Savage, C. Horak, 2015, The New England journal of medicine.

Association of PIK3CA mutation with response (ExRx) to cetuximab (C) in metastatic (met) triple-negative breast cancer (TNBC).

C. Horak, N. Palma, Kai Wang, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Hallmarks of Resistance to Immune-Checkpoint Inhibitors

Daniel K. Wells, C. Horak, B. Vincent, 2022, Cancer immunology research.

Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial.

G. Linette, C. Horak, J. Wolchok, 2016, The Lancet. Oncology.

Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial.

C. Horak, R. Sullivan, J. Sosman, 2016, The Lancet. Oncology.

MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma

D. Jackson, A. Giobbie-Hurder, C. Horak, 2018, Science Translational Medicine.

Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma

Mark W. Ball, C. Horak, E. V. Van Allen, 2018, Science.

Saccharomyces cerevisiae Complex transcriptional circuitry at the G 1 / S transition in data

M. Gerstein, J. Qian, N. Luscombe, 2006 .

Melanoma and immunotherapy bridge 2015

Andrew J. Park, A. Hauschild, J. Malvehy, 2016, Journal of Translational Medicine.

CYP9E2, CYP4C21 and related pseudogenes from German cockroaches, Blattella germanica: implications for molecular evolution, expression studies and nomenclature of P450s.

C. Horak, Z. Wen, J. G. Scott, 2001, Gene.

ExpressYourself: a modular platform for processing and visualizing microarray data

Mark Gerstein, Nicholas M. Luscombe, Nathaniel Echols, 2003, Nucleic Acids Res..

Global analysis of gene expression in yeast

Christine E. Horak, Michael Snyder, M. Snyder, 2002, Functional & Integrative Genomics.

Effect of inhibition of the lysophosphatidic acid receptor 1 on metastasis and metastatic dormancy in breast cancer.

S. Steinberg, C. Horak, P. Steeg, 2012, Journal of the National Cancer Institute.

Medroxyprogesterone acetate elevation of Nm23-H1 metastasis suppressor expression in hormone receptor-negative breast cancer.

S. Steinberg, C. Horak, M. Merino, 2005, Journal of the National Cancer Institute.

irRECIST for the Evaluation of Candidate Biomarkers of Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma: Analysis of a Phase II Prospective Clinical Trial

P. Catalano, C. Horak, G. Freeman, 2019, Clinical Cancer Research.

Clinical response, progression-free survival (PFS), and safety in patients (pts) with advanced melanoma (MEL) receiving nivolumab (NIVO) combined with ipilimumab (IPI) vs IPI monotherapy in CheckMate 069 study.

G. Linette, C. Horak, J. Wolchok, 2015 .

Cancer Treatment with Anti-PD-1/PD-L1 Agents: Is PD-L1 Expression a Biomarker for Patient Selection?

J. Hipp, C. Horak, G. Botti, 2016, Drugs.

The cetuximab experience: developing predictive biomarkers in oncology.

C. Horak, S. Khambata-Ford, C. Harbison, 2011, Personalized medicine.

c-Met Ectodomain Shedding Rate Correlates with Malignant Potential

C. Horak, J. Coleman, P. Steeg, 2006, Clinical Cancer Research.

Nm23-H1 suppresses tumor cell motility by down-regulating the lysophosphatidic acid receptor EDG2.

P. Meltzer, C. Horak, A. Elkahloun, 2007, Cancer research.

Nm 23-H 1 Suppresses Metastasis by Inhibiting Expression of the Lysophosphatidic Acid Receptor EDG 2

S. Steinberg, C. Horak, M. Merino, 2007 .

Comparison of KRAS genotype: therascreen assay vs. LNA-mediated qPCR clamping assay.

C. Horak, E. Van Cutsem, J. Denne, 2013, Clinical colorectal cancer.

848PDImpact of zumor mutation burden on nivolumab efficacy in second-line urothelial carcinoma patients: Exploratory analysis of the phase ii checkmate 275 study

Matthew D. Galsky, Alexandre Lambert, C. Horak, 2017 .

Biomarker Analysis of Neoadjuvant Doxorubicin/Cyclophosphamide Followed by Ixabepilone or Paclitaxel in Early-Stage Breast Cancer

L. Pusztai, C. Horak, O. Trifan, 2013, Clinical Cancer Research.

Updated results from a phase III trial of nivolumab (NIVO) combined with ipilimumab (IPI) in treatment-naive patients (pts) with advanced melanoma (MEL) (CheckMate 067).

D. Schadendorf, C. Horak, R. Dummer, 2016 .

House-fly cytochrome P450 CYP6D1: 5' flanking sequences and comparison of alleles.

C. Horak, S. Kasai, Z. Wen, 1999, Gene.

Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator's Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial.

D. Schadendorf, G. Linette, C. Horak, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Longitudinal Analysis of IDO and PDL1 Expression during Immune- or Targeted Therapy in Advanced Melanoma1

C. Horak, R. Dummer, M. Levesque, 2018, Neoplasia.

Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma.

C. Horak, G. Gibney, H. Inzunza, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Efficacy and Safety of Nivolumab in Patients With BRAF V600 Mutant and BRAF Wild-Type Advanced Melanoma: A Pooled Analysis of 4 Clinical Trials.

C. Horak, J. Wolchok, J. Larkin, 2015, JAMA oncology.

Nivolumab Plus Ipilimumab in Patients With Advanced Melanoma: Updated Survival, Response, and Safety Data in a Phase I Dose-Escalation Study.

C. Horak, J. Wolchok, M. Atkins, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Safety, Correlative Markers, and Clinical Results of Adjuvant Nivolumab in Combination with Vaccine in Resected High-Risk Metastatic Melanoma

C. Horak, M. Schell, G. Gibney, 2014, Clinical Cancer Research.

Peripheral and tumor immune correlates in patients with advanced melanoma treated with nivolumab (anti-PD-1, BMS-936558, ONO-4538) monotherapy or in combination with ipilimumab

J. Taube, C. Horak, J. Wolchok, 2014, Journal of Translational Medicine.

Efficacy and safety results from a phase III trial of nivolumab (NIVO) alone or combined with ipilimumab (IPI) versus IPI alone in treatment-naive patients (pts) with advanced melanoma (MEL) (CheckMate 067).

D. Schadendorf, C. Horak, R. Dummer, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Melanoma and immunotherapy bridge 2015

Andrew J. Park, David C. Smith, A. Hauschild, 2016, Journal of Translational Medicine.

Association of human endogenous retrovirus (hERV) expression with clinical efficacy of PD-1 blockade in metastatic clear cell renal cell carcinoma (mccRCC).

P. Catalano, C. Horak, G. Freeman, 2019, Journal of Clinical Oncology.

Correlation of degree of tumor immune infiltration and insertion-and-deletion (indel) burden with outcome on programmed death 1 (PD1) therapy in advanced renal cell cancer (RCC).

Mark W. Ball, C. Horak, R. Motzer, 2018 .

CYP 9 E 2 , CYP 4 C 21 and related pseudogenes from German cockroaches , Blattella germanica : implications for molecular evolution , expression studies and nomenclature of P 450 s

C. Horak, Z. Wen, J. G. Scott, 2001 .

Alterations in Gemin5 expression contribute to alternative mRNA splicing patterns and tumor cell motility.

Zhaojing Meng, Timothy D Veenstra, C. Horak, 2008, Cancer research.

Neoadjuvant doxorubicin/cyclophosphamide followed by ixabepilone or paclitaxel in early stage breast cancer and evaluation of βIII-tubulin expression as a predictive marker.

Cynthia, P. Fasching, L. Pusztai, 2013, The oncologist.

Predictive Biomarkers and Personalized Medicine Biomarker Analysis of Neoadjuvant Doxorubicin / Cyclophosphamide Followed by Ixabepilone or Paclitaxel in Early-Stage Breast Cancer

L. Pusztai, C. Horak, O. Trifan, 2013 .

Altered gene and protein expression by Nm23-H1 in metastasis suppression

C. Horak, P. Steeg, J. Marshall, 2009, Molecular and Cellular Biochemistry.

Validation of companion diagnostic for detection of mutations in codons 12 and 13 of the KRAS gene in patients with metastatic colorectal cancer: analysis of the NCIC CTG CO.17 trial.

C. Horak, S. Khambata-Ford, C. Harbison, 2013, Archives of pathology & laboratory medicine.

Peripheral and tumor immune correlates in patients with advanced melanoma treated with combination nivolumab (anti-PD-1, BMS-936558, ONO-4538) and ipilimumab.

C. Horak, J. Wolchok, M. Sznol, 2013 .

Safety and clinical activity of nivolumab (anti-PD-1, BMS-936558, ONO-4538) in combination with ipilimumab in patients (pts) with advanced melanoma (MEL).

C. Horak, J. Wolchok, M. Sznol, 2013 .

Nm23-H1 homologs suppress tumor cell motility and anchorage independent growth

C. Horak, P. Steeg, M. Lacombe, 2007, Clinical & Experimental Metastasis.

Nivolumab improved survival vs dacarbazine in patients with untreated advanced melanoma

D. Schadendorf, K. Savage, C. Horak, 2015, Journal of Translational Medicine.

Nivolumab improved survival vs dacarbazine in patients with untreated advanced melanoma

D. Schadendorf, K. Savage, C. Horak, 2015, Journal of Translational Medicine.

Clinical Safety , CorrelativeMarkers , andClinical Results of Adjuvant Nivolumab in Combination with Vaccine in Resected High-Risk Metastatic Melanoma

C. Horak, M. Schell, G. Gibney, 2015 .

PD-L1 expression as a biomarker for nivolumab (NIVO) plus ipilimumab (IPI) and NIVO alone in advanced melanoma (MEL): A pooled analysis

D. Schadendorf, C. Horak, P. Ascierto, 2016 .

Abstract CT034: GLIMMER-01: initial results from a phase 1 dose escalation trial of a first-in-class bi-sialidase (E-602) in solid tumors

C. Horak, M. Sznol, A. El-Khoueiry, 2023, Cancer Research.

The role of metastasis suppressor genes in metastatic dormancy.

C. Horak, P. Steeg, S. Shreeve, 2008, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

Metastasis gets site specific.

C. Horak, P. Steeg, 2005, Cancer cell.

Loss-of-function of PBRM1 to predict response to anti-PD-1/PD-L1 therapy in metastatic renal cell carcinoma.

C. Horak, S. Signoretti, R. Motzer, 2017 .

23LBA An open-label, randomized, phase 2 study of nivolumab (NIVO) given sequentially with ipilimumab (IPI) in patients with advanced melanoma (CheckMate 064)

C. Horak, R. Sullivan, J. Sosman, 2015 .